Exelixis, Inc. today announced that the company's Board of Directors has authorized the repurchase of up to an additional $500 million of the company's common stock before December 31, 2025. Exelixis ...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

GSA Capital Partners LLP now owns 271,983 shares of the company’s stock worth $2,176,000 after acquiring an additional 175,116 shares during the period. Baillie Gifford & Co. raised its stake in ...

In a report released today, Peter Lawson from Barclays maintained a Hold rating on Exelixis (EXEL – Research Report), with a price target of ...

Check Out Our Latest Research Report on EXEL Exelixis Stock Up 1.5 % NASDAQ:EXEL opened at $35.00 on Tuesday. Exelixis, Inc. has a 1-year low of $20.14 and a 1-year high of $37.59. The firm has a ...

ALAMEDA, Calif., February 20, 2025--Exelixis, Inc. (Nasdaq: EXEL) today announced that the company’s Board of Directors has authorized the repurchase of up to an additional $500 million of the ...

Cancer drug specialist Exelixis (NASDAQ: EXEL) was quite the stock market star on Friday. Following news that it's making a ...

EXEL boasts an average earnings surprise of 26.9%. Exelixis is also cash rich. The company has generated cash flow growth of 10.8%, and is expected to report cash flow expansion of 135.6% in 2025.

Elon Musk paid $44 billion to buy Twitter – almost certainly an overpayment – and he promptly made significant changes that ...

CEO Alex Karp has moved to sell $1.2 billion worth of the data analytics company’s stock. Discover the Best Stocks ...

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a growth stock that ...